Mycell Technologies

About Mycell Technologies

Established in January 2010, Mycell Technologies LLC operates as an intellectual property and investment holding company focused on developing proprietary liquid formulations. The firm, under the leadership of Chairman and CEO Benjamin D. Mamola, specializes in creating shelf-stable, highly concentrated Omega-3s for various applications. Its primary business involves licensing its advanced delivery system, MyCell Technology, to partners in the nutraceutical, food and beverage, and cosmetic industries.

The core of the company's offering is the patented MyCell Technology, a delivery system designed to significantly enhance the bioavailability of fat-soluble and poorly absorbed natural compounds. This technology mimics the body's natural micellization process, where fat-soluble substances are encapsulated in water-soluble shells, or micelles. This encapsulation protects active ingredients from stomach acids and allows for near-complete absorption by the body, a substantial improvement over the typical 5-15% absorption rate for such compounds. The technology is applicable to a wide range of ingredients, including Omega-3s, Curcumin, Vitamins, and CBD.

Through its wholly-owned subsidiary, Oceans Omega LLC, Mycell Technologies serves as a key supplier of stabilized Omega-3 EPA/DHA ingredients. These ingredients enable the fortification of consumer products that were previously difficult to enhance, such as clear beverages, gels, and nutritional shots. The business model is centered on providing these advanced ingredient solutions to food and beverage manufacturers, allowing them to create differentiated, high-value products. Mycell Technologies has secured significant capital through strategic investments, including a $10 million institutional financing in 2012 and a subsequent $3 million round in 2013, to fuel its growth and expand its market presence.